论文部分内容阅读
目的观察阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及对血清C反应蛋白(CRP)、免疫球蛋白水平的影响。方法选取医院收治的肺炎支原体肺炎患儿90例为研究对象,随机分为对照组和观察组,每组45例。对照组采用阿奇霉素序贯疗法治疗,观察组采用阿奇霉素序贯疗法联合孟鲁司特钠治疗,观察2组临床总有效率、治疗前后CRP及免疫球蛋白水平。结果观察组总有效率为93.3%,高于对照组的73.3%(P<0.05);与治疗前比较,2组治疗后CRP、IgE、IgG水平均降低,IgA水平均升高(P<0.01);且观察组治疗后各指标水平改善优于对照组(P<0.05)。结论小儿肺炎支原体肺炎应用阿奇霉素联合孟鲁司特钠治疗能够明显提高临床疗效,降低血清CRP水平,提高免疫功能,安全可靠。
Objective To observe the effect of azithromycin combined with montelukast sodium on children with Mycoplasma pneumoniae pneumonia and its effect on serum C-reactive protein (CRP) and immunoglobulin levels. Methods 90 cases of children with Mycoplasma pneumoniae pneumonia admitted in the hospital were selected as the research object and randomly divided into control group and observation group with 45 cases in each group. The control group was treated with azithromycin sequential therapy. The observation group was treated with azithromycin sequential therapy combined with montelukast sodium. The total effective rate of the two groups and CRP and immunoglobulin levels before and after treatment were observed. Results The total effective rate in the observation group was 93.3%, which was higher than that in the control group (73.3%, P <0.05). Compared with before treatment, the levels of CRP, IgE and IgG in both groups decreased and IgA levels increased ); And the observation group after treatment, the improvement of each index level is better than the control group (P <0.05). Conclusion The application of azithromycin combined with montelukast sodium in children with mycoplasma pneumoniae pneumonia can significantly improve clinical efficacy, reduce serum CRP levels, improve immune function, and be safe and reliable.